, Tracking Stock Market Picks
Enter Symbol:
Rating: ALKS
Overweight $74

Alkermes, Inc. (NASDAQ: ALKS) rated to Overweight with price target $74 by Barclays

Thursday,  May 21, 2015  12:25 PM ET by Dave Ficere

Barclays rated Alkermes, Inc.
(NASDAQ: ALKS) to Overweight with price target $74.

Alkermes, Inc. is a biotechnology company that develops innovative medicines designed to yield better therapeutic outcomes and improve the lives of patients with serious disease. Alkermes currently has two commercial products: RISPERDAL CONSTA, the first and only long-acting atypical antipsychotic medication approved for use in schizophrenia, and marketed worldwide by Janssen-Cilag, a wholly owned division of Johnson & Johnson; and VIVITROL the first and only once-monthly injectable medication approved for the treatment of alcohol dependence and marketed in the U.S. primarily by Cephalon, Inc. Alkermes' pipeline includes extended-release injectable, pulmonary, and oral products for the treatment of prevalent, chronic diseases such as central nervous system disorders, addiction and diabetes.


RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy